CRISPR Therapeutics AG
CRSP
NASDAQ·Healthcare·Biotechnology·Mkt cap $5.4B
$55.79
▼ -1.24%
P/E
-11.72
Mkt Cap
$5.4B
52-Wk Range
$44.12–$78.48
52-Week Range
$44.12 - $78.48
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 3.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CRISPR/Cas9 gene-editing platform
- Advanced pipeline of targeted therapies
- Strategic pharmaceutical partnerships
- Breakthrough technology with broad applications
Bear Case
1 risk
- Above-average volatility (beta 1.8).
Growth
Strong growth ahead
Expanding gene therapy market
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+8.1% over 3m
Quality
Solid
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying CRSP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 3, 2026
Reported EPS of -$0.94 vs -$1.19 consensus (+21.0% surprise). Revenue of $10.2M vs $7.4M expected (+36.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+21.0%
Revenue trend · last 8Q
—
-83%
+72%
+73%
—
-98%
+69%
+1041%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$35.0M
$865.0K
$892.0K
$889.0K
$864.0K
$1.5M
$10.2M
Margins · last 8Q
Gross
—
Operating
—
Profit
-895.3%
Wall Street consensus
4 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 25, 2026
vs Industry
How CRSP stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related